First-in-man trial of TransCon CNP in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs TransCon CNP (Primary)
- Indications Achondroplasia
- Focus Adverse reactions; First in man
- 28 Mar 2018 According to an Ascendis Pharma media release, top-line data from this study is expected in the next twelve months.
- 11 Jan 2018 New trial record
- 08 Jan 2018 According to an Ascendis Pharma media release, the company has recently initiated the regulatory process in Australia to enable this trial. The company expects to initiate dosing the subjects in the second quarter of 2018 with top-line data to be announced in the fourth quarter of 2018.